Buy Rating Backed by VALIANT Phase 2 Asthma Data and Differentiated, Infrequent-Dosing Profile for Verekitug

LifeSci Capital analyst Kate Dellorusso has maintained their bullish stance on UPB stock, giving a Buy rating on March 11.

Kate Dellorusso has given his Buy rating due to a combination of factors, primarily the strong Phase 2 VALIANT asthma data, where verekitug demonstrated Tezspire‑like efficacy with a marked reduction in annualized asthma exacerbation rates at the Q12W dose. She emphasizes that management’s recent pharmacokinetic and pharmacodynamic analysis across roughly 500 participants supports near-complete TSLP receptor coverage with infrequent dosing, which she views as a strategically differentiated and patient‑friendly profile.

Furthermore, Dellorusso highlights that higher drug exposure is predicted to deliver near-maximal efficacy at a dose that remains compatible with a single autoinjector, reinforcing the commercial attractiveness of the regimen. She also notes that although anti-drug antibody incidence is relatively high, the low and stable titers have shown no meaningful impact on lung function or exacerbation outcomes, alleviating concerns about long-term effectiveness and supporting confidence in the Phase 3 path and overall investment thesis.

In another report released on March 11, TD Cowen also maintained a Buy rating on the stock with a $0.00 price target.

Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of UPB in relation to earlier this year.